Page 11 - SaxoCell Annual Report22/23

With its 12 innova-
tive research pro- SaxoCell e.V.
jects on CAR-T and
(CAR-) NK cell Automated
therapies, gene the- production
rapies based on
designer recombi-
nases as well as Specialized Investment & Successful Innovative
clinical
regenerative appro- professionals establishment application ATMPs
CGT/GMP
of industry
aches, SaxoCell of-
fers a broad spec-
trum of therapies
New
that are tailored to partners &
the needs of pa- projects
tients. Training
Education &

SaxoCell's core competencies

These innovative cell and gene therapies are developed and optimized in Saxony and are to
be brought to automated production and finally to application with the help of our adjacent
technology platforms (OMICS, CLINICS us SYSTEMS) as well as industrial partners via
preclinical and clinical studies. Thus, the entire value chain is mapped in Saxony. In the long
term, we want to reduce the costs of such forms of therapy for patients and health insurers
and strengthen Saxony as a business location.

6